TricValve system implantation reduced symptoms at 6 months in 3 of 4 patients with severe tricuspid regurgitation, though only 1 patient survived to 12 months.
Observational (n=4)
Does TricValve system implantation improve symptoms and survival in high-risk patients with severe tricuspid regurgitation ineligible for T-TEER and surgery?
TricValve implantation offers short-term symptom reduction in high-risk patients with severe tricuspid regurgitation, but 1-year mortality remains high due to comorbidities and heart failure progression.
Background: Tricuspid regurgitation (TR) is a common valvular heart disease that often causes disabling symptoms. Caval valve implantation with the TricValve system is one of the transcatheter treatment options proposed for TR symptom reduction. With this prospective registry, we aim to summarize our early experience with TricValve system implantation. Methods: Registry participants, selected out of patients who were referred for TR treatment but who were not eligible for the transcatheter tricuspid edge-to-edge valve repair (T-TEER), were qualified for the caval valve implantation following a HeartTeam discussion. Results: Four patients (four women; median age 71 years; 67.5–77 years) in whom a one-year follow-up was completed were included in the study. The patients were highly symptomatic in the NYHA class III despite intensive diuretic treatment; all of them were considered a high-mortality risk during conventional cardiac surgery. The TricValve system was successfully implanted in all patients. At 6-month follow-up, we observed a reduction in symptoms in three out of four patients. Up to 12 months, only one patient survived, with a reduction in symptoms of NYHA class II; two patients died because of heart failure; one died due to a progression in neoplastic disease. Conclusions: In highly symptomatic TR patients who were not eligible for the T-TEER and who had a prohibitive risk of cardiac surgery, TricValve implantation led to a reduction in symptoms in a 6-month perspective. Long-term survival was limited mainly by heart failure progression and severe concomitant disorders. Further studies are needed to fully elucidate the role of caval valve implantation in the treatment of TR patients.
Rdzanek et al. (Sat,) conducted a observational in Severe Tricuspid Regurgitation (n=4). TricValve system implantation was evaluated on Symptom reduction at 6 months. TricValve system implantation reduced symptoms at 6 months in 3 of 4 patients with severe tricuspid regurgitation, though only 1 patient survived to 12 months.